Actualización de las guías del tratamiento farmacológico de la artritis reumatoide del Colegio Mexicano de Reumatología 2018

Cardiel, Mario H.; Carrillo, Sandra; Pérez, María Cristina; Andrade, Lília; Pacheco‐Tena, César; Silveira, Luis H.; Limón, Leonardo; Cerpa, Sergio; Ureña, Sergio Gutiérrez; Durán, Sergio; Palazuelos, Fedra Irazoque; López, Sandra; Ayala, Sandra Araceli Sicsik; Barile, Leonor; Sánchez, María Verónica Calyeca; Portes, Daniel Grajeda; Portela, Margarita; Bedolla, Alina Hernández; García‐Figueroa, José Luis; Montero, Mauricio; Abud-Mendoza, Carlos; Martínez-Martínez, Marco Ulises; Ostdam, David Herrera van; Pascual‐Ramos, Virginia; Merayo-Chalico, Javier; Guzmán-Sánchez, Istar; Pérez-Bastidas, María Esther; Arreola, Jorge Enrique Aguilar; Rodríguez, Alejandra López; Reyes-Cordero, Greta; Ricardez, Humberto Alfredo; Cabrera, Manuel Rodrigo de la O; Olvera-Soto, Guadalupe; Friedmann, Daniel Xibillé

doi:10.1016/j.reuma.2019.04.002

Cited by 13 publications

(3 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The aim of this study was to investigate the knowledge and attitudes about influenza vaccination as factors to vaccine uptake and hesitancy in a population with 18 19 20 21 RD from the north of Mexico.…”

Section: Introductionmentioning

confidence: 99%

Knowledge and attitudes about influenza vaccination in rheumatic diseases patients

Figueroa-Parra

Esquivel-Valerio

Santoyo-Fexas

et al. 2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Patients with rheumatic diseases (RD) have a higher risk of morbidity and mortality from vaccinepreventable infections attributed to disease activity, comorbidities, immunosuppressive therapy, and other factors. Vaccines are one of the safest and most effective public health interventions. The aim of this study was to investigate knowledge and attitudes about influenza vaccination as factors influencing vaccine uptake and hesitancy in a population with RD. A descriptive cross-sectional study was designed. A self-administered questionnaire surveyed age, RD diagnosis, ten questions about the uptake, safety and efficacy of influenza vaccine, knowledge of cost-free availability, and the relationship between influenza vaccination and RD. A total of 223 questionnaires were filled; 79.8% of patients were vaccinated for influenza at least once. Uptake by diagnosis was 80.3% in rheumatoid arthritis, 76.2% in osteoarthritis, 86.7% in lupus, 73.9% in other auto-immune diseases (AID), and 60% in other non-AID; 83.9% of patients considered influenza vaccine as safe and effective. From those who had never been vaccinated, 26.7% of patients did not consider influenza vaccine safe and effective vs. 13.5% among patients who had been vaccinated (P = .032). Only 7.6% considered that RD patients could not be vaccinated; 11.7% thought that influenza vaccine would worsen their RD symptoms. This study showed that concerns about safety, efficacy, side effects, fear of the vaccine, and knowledge of cost diminished vaccine uptake. These are factors related to confidence, complacency, and convenience as components of vaccine hesitancy that affect influenza vaccination in RD patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Knowledge and attitudes about influenza vaccination in rheumatic diseases patients

Figueroa-Parra

Esquivel-Valerio

Santoyo-Fexas

et al. 2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Rheumatoid arthritis (RA) is a chronic autoimmune disease of unknown etiology that involves genetic, environmental, immunologic, and hormonal factors [1,2]. The primary goal of RA treatment is to achieve and maintain disease remission or disease activity levels as low as possible [3]. Disease-modifying antirheumatic drugs (DMARDs) have been used to achieve these objectives [1].…”

Section: Introductionmentioning

confidence: 99%

Elevated Serum Levels of YKL-40, YKL-39, and SI-CLP in Patients with Treatment Failure to DMARDs in Patients with Rheumatoid Arthritis

Esparza-Díaz,

Gamez-Nava,

Gonzalez-Lopez

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Around 30–60% of patients with rheumatoid arthritis (RA) present treatment failure to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Chitinase-like proteins (CLPs) (YKL-40, YKL-39, SI-CLP) might play a role, as they are associated with the inflammatory process. This study aimed to evaluate CLP utility as a biomarker in the treatment failure of csDMARDs. A case–control study included 175 RA patients classified into two groups based on therapeutic response according to DAS28-ESR: responders (DAS28 < 3.2); non-responders (DAS28 ≥ 3.2). CLP serum levels were determined by ELISA. Multivariable logistic regression and receiver operating characteristic (ROC) curves were used to evaluate CLPs’ utility as biomarkers of treatment failure. Non-responders presented higher levels of YKL-40, YKL-39, and SI-CLP compared with responders (all: p < 0.001). YKL-40 correlated positively with YKL-39 (rho = 0.39, p < 0.001) and SI-CLP (rho = 0.23, p = 0.011) and YKL-39 with SI-CLP (rho = 0.34, p < 0.001). The addition of CLPs to the regression models improves diagnostic accuracy (AUC 0.918) compared to models including only clinical classical variables (AUC 0.806) p < 0.001. Non-responders were positive for all CLPs in 35.86%. Conclusions: CLPs could be considered as a useful biomarker to assess treatment failure, due to their association with clinical variables and improvement to the performance of regression models.

show abstract

“…Расширение знаний об иммунопатогенезе ИВРЗ и роли JAK в регуляции иммунного ответа и воспаления создали предпосылки для изучения эффективности ТОФА при других ИВРЗ и «неревматических» иммуновоспалительных заболеваний [3,4,[11][12][13][14]. ТОФА классифицируется как «таргетный» синтетический базисный противовоспалительный препарат (тсБПВП) [15] и включен в международные [16][17][18][19][20][21][22][23][24][25] и российские [26] клинические рекомендации по лечению РА, а также в рекомендации Американской коллегии ревматологов (ACR) по лечению ПсА [27].…”

unclassified

Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)

Насонов

Авдеева²,

Лила

2020

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Расшифровка механизмов патогенеза иммуновоспалительных ревматических заболеваний (ИВРЗ), основными формами кото-рых являются ревматоидный артрит (РА), спондилоартриты (СпА), включающие анкилозирующий спондилит (АС) и псориатиче-П р о г р е с с в р е в м а т о л о г и и в X X I в е к е Насонов Е.Л.научный руководитель ФГБНУ «НИИР им. В.А. Насоновой», академик РАН, профессор, докт. мед. наук 1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»,

show abstract

Actualización de las guías del tratamiento farmacológico de la artritis reumatoide del Colegio Mexicano de Reumatología 2018

Cited by 13 publications

References 143 publications

Knowledge and attitudes about influenza vaccination in rheumatic diseases patients

Knowledge and attitudes about influenza vaccination in rheumatic diseases patients

Elevated Serum Levels of YKL-40, YKL-39, and SI-CLP in Patients with Treatment Failure to DMARDs in Patients with Rheumatoid Arthritis

Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)

Contact Info

Product

Resources

About